Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1921188 | 0.85 | — | — | |
| SCHEMBL4847 | 0.76 | — | — | |
| SCHEMBL6901393 | 0.76 | — | — | |
| SCHEMBL11241847 | 0.76 | — | — | |
| SCHEMBL18773606 | 0.76 | EPHX2 (0.33) | EPHX2 | |
| SCHEMBL9393516 | 0.76 | EPHX2 (0.33) | EPHX2 | |
| SCHEMBL29700 | 0.76 | — | — | |
| SCHEMBL4456910 | 0.76 | EPHX2 (0.33) | EPHX2 | |
| SCHEMBL750102 | 0.76 | — | — | |
| SCHEMBL24394262 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2522669-B1 | 3-Spirocyclic indolyl derivatives useful as ORL-1 receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2016-12-28 | — | — | EP | claimed |
| EP-2522669-A1 | 3-Spirocyclic indolyl derivatives useful as ORL-1 receptor modulators | Janssen Pharmaceutica NV (BE) | 2012-11-14 | — | — | EP | claimed |
| EP-1890696-A2 | NOVEL 3-SPIROCYCLIC INDOLYL DERIVATIVES USEFUL AS ORL-1 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-27 | — | — | EP | claimed |
| US-20070112016-A1 | Novel 3-spirocyclic indolyl derivatives useful as ORL-1 receptor modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-05-17 | — | — | US | claimed |
| WO-2006130416-A2 | NOVEL 3-SPIROCYCLIC INDOLYL DERIVATIVES USEFUL AS ORL-1 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-12-07 | — | — | WO | claimed |
| EP-2522669-B1 | 3-Spirocyclic indolyl derivatives useful as ORL-1 receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2016-12-28 | — | — | EP | disclosed |
| EP-2522669-A1 | 3-Spirocyclic indolyl derivatives useful as ORL-1 receptor modulators | Janssen Pharmaceutica NV (BE) | 2012-11-14 | — | — | EP | disclosed |
| US-20110004019-A1 | Parakeratosis Inhibitor, Pore-Shrinking Agent, Or Rough Skin Inhibiting/Ameliorating Agent, And External Composition For Skin Containing The Same | SHISEIDO COMPANY LTD. (JP) | 2011-01-06 | — | — | US | disclosed |
| EP-2255780-A1 | PARAKERATOSIS INHIBITOR, PORE SHRINKING AGENT OR AGENT FOR PREVENTING OR IMPROVING ROUGH SKIN, AND COMPOSITION FOR EXTERNAL USE ON THE SKIN CONTAINING THE SAME | Shiseido Company, Ltd. (JP) | 2010-12-01 | — | — | EP | disclosed |
| US-7655670-B2 | 1-((tetrahydropyran-2-yl)oxy-ethyl)-5-tert-butoxycarbonyl-spiro[indoline-3,4'-piperidin]-2-one; ORL-1 (orphan opioid receptor) G-protein coupled receptor; brain, psychological disorders | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-02-02 | — | — | US | disclosed |
| EP-1890696-A2 | NOVEL 3-SPIROCYCLIC INDOLYL DERIVATIVES USEFUL AS ORL-1 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-02-27 | — | — | EP | disclosed |
| US-20070112016-A1 | Novel 3-spirocyclic indolyl derivatives useful as ORL-1 receptor modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-05-17 | — | — | US | disclosed |
| US-5155113-A | Administering 5-fluorouracil and derivatives with pyridine and pyridone derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1992-10-13 | — | — | US | disclosed |
| EP-0180188-B1 | A COMPOSITION FOR INCREASING THE ANTI-CANCER ACTIVITY OF AN ANTI-CANCER COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1992-04-15 | — | — | EP | disclosed |
| EP-0180897-B1 | 5-FLUOROURACIL DERIVATIVES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1991-08-07 | — | — | EP | disclosed |
| EP-0436902-A1 | 5-Fluorouracil derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1991-07-17 | — | — | EP | disclosed |
| US-4983609-A | Anticancer agents | OTSUKA PHARMACEUTICAL (JP) | 1991-01-08 | — | — | US | disclosed |
| US-4864021-A | ANTICARCINOGENIC AGENTS, ANTITUMOR AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1989-09-05 | — | — | US | disclosed |
| EP-0180897-A2 | 5-Fluorouracil derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-05-14 | — | — | EP | disclosed |
| EP-0180188-A2 | A composition for increasing the anti-cancer activity of an anti-cancer compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112016-A1 | Novel 3-spirocyclic indolyl derivatives useful as ORL-1 receptor modulators | OXER1, OGFRL1, NR1H2 | EPHX2 4008/4885 |
| US-20110004019-A1 | Parakeratosis Inhibitor, Pore-Shrinking Agent, Or Rough Skin Inhibiting/Ameliorating Agent, And External Composition For Skin Containing The Same | CUTA, GLRA3, ARGLU1 | EPHX2 4857/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.